ACOG Issues New Menopause Care Guidelines
The American College of Obstetricians and Gynecologists published updated recommendations emphasizing individualized treatment for menopause symptoms.
Updated on Nov. 10, 2026 in Women’s Health
The American College of Obstetricians and Gynecologists published new menopause care recommendations in the November 2026 issue of Obstetrics & Gynecology. The guidance urges clinicians to tailor treatment to each woman's symptoms, medical history and risk factors, covering both hormonal and non-hormonal options.
Why it matters
Menopause symptoms such as hot flashes, night sweats, sleep disturbances and mood changes can significantly disrupt daily life, and the guidance addresses a subject many women have historically hesitated to raise with clinicians. The recommendations arrive as U.S. regulators move to revise hormone therapy labeling.
Menopause typically begins around age 50 to 51, but about 12% of women experience it before 45 and roughly 3.5% develop premature ovarian insufficiency before 40. More than one billion women worldwide are currently over age 50, and the source does not detail how outcomes under the new guidance will be tracked.
The players
American College of Obstetricians and Gynecologists (ACOG)
ACOG is a professional medical organization representing obstetricians and gynecologists, whose clinical guidance is widely used by physicians in the United States and internationally.
U.S. Food and Drug Administration (FDA)
The FDA is the federal agency responsible for regulating drugs in the United States, including the labeling of hormone therapy products.
The details
The guidance stresses that menopause care should be based on each woman's symptoms, medical history and treatment risks rather than a single standard approach. It highlights cognitive behavioral therapy, regular physical activity and balanced nutrition alongside pharmaceutical options.
Timeline
November 2025: FDA announced plans to remove certain boxed warnings from menopause hormone therapy products.
2003: Original hormone therapy boxed warnings covering cardiovascular risk, breast cancer and dementia were introduced.
November 2026: ACOG menopause recommendations were published in Obstetrics & Gynecology.
Big Picture
The 2003 boxed warnings on hormone therapy, which covered cardiovascular risk, breast cancer and dementia, shaped prescribing for two decades. The new ACOG guidance and the FDA's planned label revisions signal a shift away from that restrictive framing toward individualized care.
Women experiencing hot flashes, night sweats or sleep disruption can discuss both hormonal and non-hormonal options with their clinicians. Lifestyle measures such as cognitive behavioral therapy, regular physical activity and balanced nutrition are highlighted as part of care.
The takeaway
Menopause care works best when treatment is matched to a woman's own symptoms, history and risks. Talking openly with a clinician about sleep, mood and hot flashes is a practical first step.
Further reading
Explore more in Women's Health for context on menopause and related care.
